Effect of supplementary feeding on the side effects associated with cancer therapy with taxanes

• Conditions: C50; C34; C61; C00; C01; C02; C05; C08; C03; C56

• Registration Number: DRKS00005950
• Lead Sponsor: ribosepharm division - Hikma Pharma GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-03-06
• Study Completion: 2020-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 712

Inclusion Criteria

Patients:
-Consent eligible adult
-The decision for the prescribed therapy falls the physican individually before the inclusion of nis taxanes
-Prescribing information physican used
This Nis is offered oncologically active, practicing physicians

Exclusion Criteria

People less than 18 years

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The influence of the nutritional status of patients on the severity of the side effects of treatment with taxanes (Ribodocel® or Ribotax®)

Secondary Outcome Measures

Name	Time	Method
Influence of other dietary supplements on the side effects of treatment with taxanes (Ribodocel® or Ribotax®)